Published in J Urol on September 25, 2011
Phase I Study MR-guided SBRT to PCa (MRgRTPCa) | NCT03935308
Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA (2015) 9.02
Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol (2012) 2.89
Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol (2013) 2.43
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35
Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol (2012) 2.06
Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers. BJU Int (2014) 1.75
Detecting Prostate Cancer. Dtsch Arztebl Int (2015) 1.71
The role of magnetic resonance imaging in delineating clinically significant prostate cancer. Urology (2014) 1.66
Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. J Urol (2014) 1.55
Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging (2013) 1.54
Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU Int (2012) 1.42
Multimodality image fusion-guided procedures: technique, accuracy, and applications. Cardiovasc Intervent Radiol (2012) 1.18
Current status of magnetic resonance imaging (MRI) and ultrasonography fusion software platforms for guidance of prostate biopsies. BJU Int (2014) 1.18
Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol (2013) 1.17
Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging. Radiology (2015) 1.16
Transperineal biopsy of the prostate--is this the future? Nat Rev Urol (2013) 1.14
Performance of multiparametric MRI in men at risk of prostate cancer before the first biopsy: a paired validating cohort study using template prostate mapping biopsies as the reference standard. Prostate Cancer Prostatic Dis (2013) 1.05
The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol. BMJ Open (2014) 1.03
Automated prostate cancer detection via comprehensive multi-parametric magnetic resonance imaging texture feature models. BMC Med Imaging (2015) 1.02
Decision support system for localizing prostate cancer based on multiparametric magnetic resonance imaging. Med Phys (2012) 0.96
Imaging of prostate cancer: a platform for 3D co-registration of in-vivo MRI ex-vivo MRI and pathology. Proc SPIE Int Soc Opt Eng (2012) 0.96
The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int (2013) 0.94
Multiparametric MRI in biopsy guidance for prostate cancer: fusion-guided. Biomed Res Int (2014) 0.90
Active surveillance for prostate cancer: an underutilized opportunity for reducing harm. J Natl Cancer Inst Monogr (2012) 0.90
Multiparametric magnetic resonance imaging and image-guided biopsy to detect seminal vesicle invasion by prostate cancer. J Endourol (2014) 0.89
Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up. Diagn Interv Radiol (2014) 0.89
The current and future role of magnetic resonance imaging in prostate cancer detection and management. Transl Androl Urol (2015) 0.89
Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology. J Urol (2016) 0.88
Automated prostate cancer detection using T2-weighted and high-b-value diffusion-weighted magnetic resonance imaging. Med Phys (2015) 0.88
Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies. PLoS One (2015) 0.86
Magnetic Resonance Imaging-Ultrasound Fusion-Guided Prostate Biopsy: Review of Technology, Techniques, and Outcomes. Curr Urol Rep (2016) 0.86
Magnetic resonance imaging for prostate cancer: Comparative studies including radical prostatectomy specimens and template transperineal biopsy. Prostate Int (2015) 0.85
Five-point Likert scaling on MRI predicts clinically significant prostate carcinoma. BMC Urol (2015) 0.85
Imaging modalities in focal therapy: patient selection, treatment guidance, and follow-up. Curr Opin Urol (2014) 0.85
Multiparametric ultrasound in the detection of prostate cancer: a systematic review. World J Urol (2015) 0.84
Efficacy of using three-tesla magnetic resonance imaging diagnosis of capsule invasion for decision-making about neurovascular bundle preservation in robotic-assisted radical prostatectomy. Korean J Urol (2013) 0.84
Prostate cancer discrimination in the peripheral zone with a reduced field-of-view T(2)-mapping MRI sequence. Magn Reson Imaging (2015) 0.84
Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: quantitative analysis of imaging contour compared to whole-mount histopathology. Radiother Oncol (2014) 0.84
Framework for 3D histologic reconstruction and fusion with in vivo MRI: Preliminary results of characterizing pulmonary inflammation in a mouse model. Med Phys (2015) 0.83
Functional and molecular imaging of localized and recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2013) 0.83
Focal ablation of prostate cancer: four roles for magnetic resonance imaging guidance. Can J Urol (2013) 0.82
Image fusion during vascular and nonvascular image-guided procedures. Tech Vasc Interv Radiol (2013) 0.82
Image-guided focal therapy for prostate cancer. Diagn Interv Radiol (2014) 0.82
Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer. Prostate Cancer Prostatic Dis (2013) 0.81
Magnetic resonance imaging-guided prostate biopsy: present and future. Korean J Radiol (2015) 0.80
Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project. World J Urol (2016) 0.80
The role of pathology correlation approach in prostate cancer index lesion detection and quantitative analysis with multiparametric MRI. Acad Radiol (2015) 0.80
Detection of prostate cancer with multiparametric MRI (mpMRI): effect of dedicated reader education on accuracy and confidence of index and anterior cancer diagnosis. Abdom Imaging (2015) 0.79
Prostate Radiotherapy in the Era of Advanced Imaging and Precision Medicine. Prostate Cancer (2016) 0.78
Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance. Prostate Cancer Prostatic Dis (2016) 0.78
Multiparametric MRI guidance in first-time prostate biopsies: what is the real benefit? Diagn Interv Radiol (2015) 0.78
Use of magnetic resonance imaging to accurately detect and stage prostate cancer: the hype and the hope. J Urol (2011) 0.78
Prostate MRI: access to and current practice of prostate MRI in the United States. J Am Coll Radiol (2014) 0.78
Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers. Future Oncol (2016) 0.78
MRI-Guided Prostate Biopsy of Native and Recurrent Prostate Cancer. Semin Intervent Radiol (2016) 0.78
Optimizing safety and accuracy of prostate biopsy. Curr Opin Urol (2016) 0.77
Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4-10 ng/mL Who Underwent TRUS-Guided Prostate Biopsy: The Utilization of PAMD Score. Biomed Res Int (2015) 0.77
MR Spectroscopic Imaging of Peripheral Zone in Prostate Cancer Using a 3T MRI Scanner: Endorectal versus External Phased Array Coils. Magn Reson Insights (2013) 0.77
Stiffness of benign and malignant prostate tissue measured by shear-wave elastography: a preliminary study. Eur Radiol (2016) 0.77
Is magnetic resonance/ultrasound fusion prostate biopsy better than systematic prostate biopsy? An updated meta- and trial sequential analysis. Oncotarget (2015) 0.76
Tissue-scale, personalized modeling and simulation of prostate cancer growth. Proc Natl Acad Sci U S A (2016) 0.75
AUTHOR'S REPLY. Cent European J Urol (2016) 0.75
PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER. Expert Rev Precis Med Drug Dev (2016) 0.75
Prototype Design and Phantom Evaluation of a Device for Co-registered MRI/TRUS Imaging of the Prostate. Clin Image Based Proced (2014) 0.75
Prostate cancer detection using multiparametric 3 - tesla MRI and fusion biopsy: preliminary results. Int Braz J Urol (2016) 0.75
Effect of Prostate Magnetic Resonance Imaging/Ultrasound Fusion-guided Biopsy on Radiation Treatment Recommendations. Int J Radiat Oncol Biol Phys (2016) 0.75
Prostate biopsy for the interventional radiologist. J Vasc Interv Radiol (2014) 0.75
Apparatus for Histological Validation of In Vivo and Ex Vivo Magnetic Resonance Imaging of the Human Prostate. Front Oncol (2017) 0.75
Prostate MRI: a national survey of Urologist's attitudes and perceptions. Int Braz J Urol (2016) 0.75
Comparison of initial and tertiary centre second opinion reads of multiparametric magnetic resonance imaging of the prostate prior to repeat biopsy. Eur Radiol (2016) 0.75
Defining the radiobiology of prostate cancer progression: An important question in translational prostate cancer research. Exp Biol Med (Maywood) (2014) 0.75
Application of an unsupervised multi-characteristic framework for intermediate-high risk prostate cancer localization using diffusion-weighted MRI. Magn Reson Imaging (2016) 0.75
MR Imaging Biomarkers in Oncology Clinical Trials. Magn Reson Imaging Clin N Am (2016) 0.75
Improved Magnetic Resonance Imaging-Pathology Correlation With Imaging-Derived, 3D-Printed, Patient-Specific Whole-Mount Molds of the Prostate. Invest Radiol (2017) 0.75
Prostate Cancer: A Correlative Study of Multiparametric MR Imaging and Digital Histopathology. Radiology (2017) 0.75
[Multiparametric imaging with simultaneous MRI/PET : Methodological aspects and possible clinical applications]. Z Rheumatol (2015) 0.75
Current Ability of Multiparametric Prostate Magnetic Resonance Imaging and Targeted Biopsy to Improve the Detection of Prostate Cancer. Urol Pract (2014) 0.75
Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer. Balkan Med J (2017) 0.75
Customized Tool for the Validation of Optical Coherence Tomography in Differentiation of Prostate Cancer. Technol Cancer Res Treat (2016) 0.75
Molecular alterations in prostate cancer and association with MRI features. Prostate Cancer Prostatic Dis (2017) 0.75
Spatial Tracking of Targeted Prostate Biopsy Locations: Moving Towards Effective Focal Partial Prostate Gland Ablation with Improved Treatment Planning. Curr Urol Rep (2017) 0.75
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature (2011) 6.57
von Hippel-Lindau disease. Lancet (2003) 6.20
Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer. N Engl J Med (2015) 5.66
Imaging of angiogenesis: from microscope to clinic. Nat Med (2003) 5.51
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 5.47
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell (2002) 5.10
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Rapid cancer detection by topically spraying a γ-glutamyltranspeptidase-activated fluorescent probe. Sci Transl Med (2011) 4.72
Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol (2013) 4.64
Post-analysis follow-up and validation of microarray experiments. Nat Genet (2002) 4.61
Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50
The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell (2002) 4.13
Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond) (2008) 4.08
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02
The Budd-Chiari syndrome. N Engl J Med (2004) 3.95
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One (2008) 3.87
Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. BMC Bioinformatics (2004) 3.65
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A (2006) 3.51
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev (2010) 3.35
Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol (2008) 3.30
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med (2008) 3.15
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology (2010) 3.12
Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol Biomarkers Prev (2002) 3.12
Robotic partial nephrectomy for complex renal tumors: surgical technique. Eur Urol (2007) 3.07
Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol (2002) 3.06
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology (2005) 2.99
Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. Cancer (2012) 2.95
Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet (2003) 2.88
Can magnetic resonance-ultrasound fusion biopsy improve cancer detection in enlarged prostates? J Urol (2013) 2.81
Imaging prostate cancer: a multidisciplinary perspective. Radiology (2007) 2.79
Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med (2011) 2.76
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet (2012) 2.71
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A (2007) 2.71
High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst (2005) 2.70
Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol (2013) 2.62
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst (2005) 2.60
Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol (2012) 2.59
Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol (2012) 2.55
In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res (2009) 2.51
Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. Circ Res (2003) 2.50
Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett (2007) 2.46
LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther (2009) 2.43
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med (2012) 2.42
Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38